Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Solvay's Cell-Derived Influenza Vaccine vs Influvac
NCT00999206Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Jan 2010
- Primary completion
- Aug 2010
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of cell-derived influenza vaccine in influenza (4 arms), sponsored by Abbott Laboratories. Primary endpoint: Anti-HA antibody titers and derived parameters at 3 weeks. Started Jan 2010; status: completed.
02
Drugs
cell-derived influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00999206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00999206.